0
Abstract: Slide Presentations |

OUTCOMES OF LUNG TRANSPLANT RECIPIENTS (LTR) PREVIOUSLY INFECTED WITH HEPATITIS C VIRUS FREE TO VIEW

Hina Sahi, MD*; Marie Budev, DO; Holli Blazey, Other; Atul Mehta, MBBS
Author and Funding Information

Cleveland Clinic Foundation, Cleveland, OH


Chest


Chest. 2005;128(4_MeetingAbstracts):213S. doi:10.1378/chest.128.4_MeetingAbstracts.213S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Outcomes of Lung Transplant in Hepatitis C virus (HCV) positive Recipients is not known. We describe our experience with 5 such patients.

METHODS:  Charts of LTR known to be HCV positive prior to transplantation were reviewed for demographics, HCV etiology, HCV RNA viral load pre and post transplantation, liver biopsy results, transaminase levels during various points post transplantation, the development of acute hepatitis and survival.

RESULTS:  454 lung transplants were performed during a 14 year period, only five patients (1%) [age (yrs± SD): 48 ± 9.7, 3 females], were anti-HCV seropositive. Etiology of HCV infection included IVDA (n=1), unknown causes (n=4), and two patients had concomitant liver disease due to alpha-1-antitrypsin deficiency and cystic fibrosis. All patients were diagnosed with HCV prior to transplantation and confirmed with HCV qualitative RNA testing. All recipients had disease severity documented by liver biopsy (minimal peri portal fibrosis n=3, no cirrhosis n=5). The median duration from HCV diagnosis to transplantation was 2 years [inter quartile range, 1 to 8.2 yrs). Pre transplantation median quantitative HCV RNA levels were 50,300 IU/ml [inter quartile range, 16,897 to 200,780,000 IU/ml]. Post transplantation median quantitative HCV RNA level were noted to markedly increase [level (IU/ml): 2,470,000 IU/ml (inter quartile range, 646,825 to 2,897,500 IU/ml)]. There was no statistically significant increase in transaminase levels pre and post LTX despite increase in HCV RNA levels. The longest surviving patient in this cohort is 5 yrs post transplantation, the shortest survival being 8 months. The patient died of respiratory complications with no evidence of hepatic failure at the time of death [mean survival (months ± SD): 32.6±23.9].

CONCLUSION:  Although viral loads tended to significantly increase post transplantation, there was no significant difference in the episodes of acute hepatitis, hepatic failure or cirrhosis during the duration of follow up. Post transplant monitoring of quantitative RNA HCV levels was not of any prognostic value.

CLINICAL IMPLICATIONS:  Further studies are needed to provide guidelines for monitoring of this population post transplantation.

DISCLOSURE:  Hina Sahi, None.

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543